Objective:To study the effects of Yishen Qutong granula on pain sensitization and bone destruction of rats with bone cancer pain.Methods:Walker256 cells were passaged in ascites and injected into the tibia of female W...Objective:To study the effects of Yishen Qutong granula on pain sensitization and bone destruction of rats with bone cancer pain.Methods:Walker256 cells were passaged in ascites and injected into the tibia of female Wistar rats to prepare the bone cancer pain model.On the 14th day after model establishment,60 rats were randomly divided into model group,sham-operated group,Yishen Qutong granula low,middle,high dose group and tramadol hydrochloride positive control group.After continuous administration for 14 days,the mechanical pain threshold,thermal threshold and weight-bearing difference of both hind limbs were observed.Results:Compared with the model group,Yishen Qutong groups increased the mechanical pain threshold,thermal pain threshold and reduced the weight difference of both hind limbs(P<0.05).Compared with the positive drug group,there was no significant difference in increasing the mechanical pain threshold and thermal pain threshold of rats in the medium dose group of Yishen Qutong(P>0.05),and Yishen Qutong granula significantly reduced the weight-bearing difference of hind limbs in all groups(P<0.05).Conclusion:Yishen Qutong granula can relieve pain sensitization and alleviate bone damage in rats with bone cancer pain.展开更多
Objective:To observe the effect of tetradecylene naphthalene soft capsule combined with Yishen Gubenyutong Decoction on bone metabolism and bone turnover in patients with osteoporosis and its clinical efficacy.Methods...Objective:To observe the effect of tetradecylene naphthalene soft capsule combined with Yishen Gubenyutong Decoction on bone metabolism and bone turnover in patients with osteoporosis and its clinical efficacy.Methods:A total of 100 patients with primary osteoporosis(all were treated by our hospital from February 2017 to June 2018)were divided into two groups.The control group(50 cases)was given to menatetrenone capsules.Treatment,observation group(50 cases)combined with Yishen Gubenqiaotongtong on the basis of the treatment of the control group,6 months for a course of treatment.The bone metabolic markers,bone mineral density changes and clinical efficacy were measured before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group.After treatment,the observation group showed serum calcium(Ca),serum alkaline phosphatase(ALP)and typeⅠcollagen.The level of cross-linked C-terminal peptide(CTX-1)was lower than that of the control group.After treatment,the osteocalcin(OC)in the observation group was higher than that in the control group,and the bone mineral density(BMD)of lumbar vertebrae L2-4,femoral neck and femur trochanter in the observation group were higher than those in the control group.Conclusion:Menatetrenone soft capsule combined with Yishen Gubenyutong Decoction has good clinical effect on osteoporosis patients and it is worth further promotion in clinic.展开更多
Cancer-related fatigue(CRF)is associated with cancer-related anemia(CRA).As the common comorbidities of cancer,both of them can seriously affect the quality of patient life.Yishen Qutong Granules(益肾祛痛颗粒,YSQTG)ha...Cancer-related fatigue(CRF)is associated with cancer-related anemia(CRA).As the common comorbidities of cancer,both of them can seriously affect the quality of patient life.Yishen Qutong Granules(益肾祛痛颗粒,YSQTG)have achieved good curative effects in the treatment of CRA.However,the mechanism of whether it can alleviate CRF needs further confirmation.We used network pharmacology and molecular docking to investigate the molecular mechanism and the effective compounds of the prescription.Through the analysis and research in this paper,we obtained 76 effective compounds and 76 drug-disease intersection targets to construct a network,indicating that quercetin,luteolin,baicalein,β-sitosterol and stigmasterol were possibly the most important compounds in YSQTG.The key targets of YSQTG for CRF were mainly enriched in IL-17 and TNF pathways.816 GO entries and 113 pathways were obtained by GO and KEGG enrichment,respectively,which proved that YSQTG might have a comprehensive therapeutic effect on CRF mainly through regulating IL-17,TNF,MAPK,NF-κB and chemokines,as well as cholinergic synapse and 5-HT synapse pathways.The results of molecular docking showed thatβ-sitosterol and stigmasterol could form PI-Alkyl or Alkyl hydrophobic interactions with CXCL8 and ESR1 at residues LEU25,ARG26,PHE65,ALA69 and LEU346,ALA350,LEU391,PHE404,LEU525,VAL533,respectively.In conclusion,the therapeutic effect of YSQTG on CRF is based on the comprehensive pharmacological effect of multicomponent,multitarget,and multichannel pathways.This study provides a theoretical basis for further experimental research.展开更多
Objective:To discuss the clinical study on Fengshi Qutong capsules combined with diclofenac sodium in the treatment of ankylosing spondylitis.Methods:80 patients who were treated for ankylosing spondylitis from June 2...Objective:To discuss the clinical study on Fengshi Qutong capsules combined with diclofenac sodium in the treatment of ankylosing spondylitis.Methods:80 patients who were treated for ankylosing spondylitis from June 2019 to June 2020 were selected and divided into two groups.The experimental group was treated with Fengshi Qutong capsules combined with diclofenac sodium,and the control group was treated with sulfasalazine enteric-coated tablets.Results:The treatment efficacy,VAS score,BASDAI score,BASFI score,CRP level,TNF-α level,IL-Iβ level,and the incidence of adverse reactions between the two groups were significantly different(P<0.05).Conclusion:The application of Fengshi Qutong capsules combined with diclofenac sodium in the treatment of patients with ankylosing spondylitis is beneficial to improve the treatment efficacy,reduce the levels of CRP,TNF-α,and IL-Iβ,reduce the incidence of adverse reactions,and reduce the VAS,BASDAI and BASFI scores,rendering it of important clinical value.展开更多
Objective: To explore the potential mechanism of Yishen Qutong Granules(YSQTG) for the treatment of esophageal cancer using network pharmacology and experimental research. Methods: The effective components and molecul...Objective: To explore the potential mechanism of Yishen Qutong Granules(YSQTG) for the treatment of esophageal cancer using network pharmacology and experimental research. Methods: The effective components and molecular mechanism of YSQTG in treating esophageal cancer were expounded based on network pharmacology and molecular docking. The key compound was identified by high-performance liquid chromatography and mass spectrometry(HPLC-MS) to verify the malignant phenotype of the key compounds in the treatment of esophageal cancer. Then, the interaction proteins of key compounds were screened by pull-down assay combined with mass spectrometry. RNA-seq was used to screen the differential genes in the treatment of esophageal cancer by key compounds, and the potential mechanism of key compounds on the main therapeutic targets was verified. Results: Totally 76 effective compounds of YSQTG were found, as well as 309 related targets, and 102 drug and disease interaction targets. The drug-compound-target network of YSQTG was constructed, suggesting that quercetin, luteolin, wogonin, kaempferol and baicalein may be the most important compounds, while quercetin had higher degree value and degree centrality, which might be the key compound in YSQTG. The HPLC-MS results also showed the stable presence of quercetin in YSQTG. By establishing a protein interaction network, the main therapeutic targets of YSQTG in treating esophageal cancer were Jun proto-oncogene, interleukin-6, tumor necrosis factor, and RELA proto-oncogene. The results of cell function experiments in vitro showed that quercetin could inhibit proliferation, invasion, and clonal formation of esophageal carcinoma cells. Quercetin mainly affected the biological processes of esophageal cancer cells, such as proliferation, cell cycle, and cell metastasis. A total of 357 quercetin interacting proteins were screened, and 531 genes were significantly changed. Further pathway enrichment analysis showed that quercetin mainly affects the metabolic pathway, MAPK signaling pathway, and nuclear factor kappa B(NF-κB) signaling pathway, etc. Quercetin, the key compound of YSQTG, had stronger binding activity by molecular docking. Pull-down assay confirmed that NF-κB was a quercetin-specific interaction protein, and quercetin could significantly reduce the protein level of NF-κB, the main therapeutic target. Conclusion: YSQTG can be multi-component, multi-target, multi-channel treatment of esophageal cancer, it is a potential drug for the treatment of esophageal cancer.展开更多
目的:探讨通络祛痛膏联合塞来昔布治疗风湿瘀阻证膝骨关节炎(knee osteoarthritis,KOA)的效果。方法:选取2021年1—12月徐州市中心医院骨科收治的130例风湿瘀阻证KOA患者。根据简单信封随机法将其分为对照组和观察组,各65例。对照组给...目的:探讨通络祛痛膏联合塞来昔布治疗风湿瘀阻证膝骨关节炎(knee osteoarthritis,KOA)的效果。方法:选取2021年1—12月徐州市中心医院骨科收治的130例风湿瘀阻证KOA患者。根据简单信封随机法将其分为对照组和观察组,各65例。对照组给予塞来昔布胶囊,观察组在对照组基础上给予通络祛痛膏。比较两组治疗前后症状评分、临床疗效及不良反应。结果:治疗后,两组KOA严重性指数(index of severity of osteoarthritis,ISOA)评分低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组临床疗效优于对照组,总有效率高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率略低于对照组,但差异无统计学意义(P>0.05),观察组未出现与中药外敷相关的局部皮肤过敏反应。结论:通络祛痛膏联合塞来昔布治疗KOA,能够缓解症状,且不增加药物相关的不良反应,用药安全性良好。展开更多
目的验证益肾祛痛颗粒(Yishen Qutong Granule,YSQTKL)对小鼠乳腺癌骨转移的抑制效果并探讨其作用机制。方法随机将5周龄BABL/c小鼠分为空白组、假手术组、模型组、YSQTKL高中低剂量组,每组8只,胫骨种植4T1.2细胞制备乳腺癌骨转移模型后...目的验证益肾祛痛颗粒(Yishen Qutong Granule,YSQTKL)对小鼠乳腺癌骨转移的抑制效果并探讨其作用机制。方法随机将5周龄BABL/c小鼠分为空白组、假手术组、模型组、YSQTKL高中低剂量组,每组8只,胫骨种植4T1.2细胞制备乳腺癌骨转移模型后,分别给予蒸馏水或相应浓度YSQTKL溶液灌胃,4周后处死取材,用Micro-CT分析松质骨骨含量/组织含量[bone volume/tissue volume(BV/TV)]、松质骨厚度[trabecular bone thickness(Tb.Th)]、松质骨数目[trabecular bone number(Tb.N)]以及松质骨间隙[trabecular bone separation(Tb.Sp)]等骨质破坏情况,测量骨转移瘤瘤重,HE染色进行组织学诊断,免疫组化法检测骨桥蛋白(Osteopontin,OPN)的表达情况。结果除空白组及假手术组外,造模各组均成瘤,组织学诊断显示乳腺癌骨转移。相对于模型组,YSQTKL低剂量组瘤重更小,差异具有统计学意义(P<0.05);Micro-CT结果显示,相对于空白组及假手术组,模型组松质骨除Tb.N无差异外,BV/TV、Tb.Th以及Tb.Sp均升高(P<0.05),而YSQTKL组松质BV/TV、Tb.Th以及Tb.Sp较模型组降低(P<0.05),骨破坏程度更低;免疫组化结果显示,相对于空白组及假手术组,模型组OPN表达升高,而YSQTKL各组OPN表达较模型组低,其中低剂量组差异具有统计学意义(P<0.05)。结论益肾祛痛颗粒可抑制小鼠乳腺癌骨转移,且下调骨桥蛋白表达是其可能作用机制。展开更多
基金General Program of National Natural Science Foundation of China(No.81873283)Special Project of"Ten Diseases and Ten Drugs"of Beijing Municipal Commission of Science and Technology(No.z171100001717017)。
文摘Objective:To study the effects of Yishen Qutong granula on pain sensitization and bone destruction of rats with bone cancer pain.Methods:Walker256 cells were passaged in ascites and injected into the tibia of female Wistar rats to prepare the bone cancer pain model.On the 14th day after model establishment,60 rats were randomly divided into model group,sham-operated group,Yishen Qutong granula low,middle,high dose group and tramadol hydrochloride positive control group.After continuous administration for 14 days,the mechanical pain threshold,thermal threshold and weight-bearing difference of both hind limbs were observed.Results:Compared with the model group,Yishen Qutong groups increased the mechanical pain threshold,thermal pain threshold and reduced the weight difference of both hind limbs(P<0.05).Compared with the positive drug group,there was no significant difference in increasing the mechanical pain threshold and thermal pain threshold of rats in the medium dose group of Yishen Qutong(P>0.05),and Yishen Qutong granula significantly reduced the weight-bearing difference of hind limbs in all groups(P<0.05).Conclusion:Yishen Qutong granula can relieve pain sensitization and alleviate bone damage in rats with bone cancer pain.
基金Scientific Research Project of Guangdong Traditional Chinese Medicine Bureau(20191292).
文摘Objective:To observe the effect of tetradecylene naphthalene soft capsule combined with Yishen Gubenyutong Decoction on bone metabolism and bone turnover in patients with osteoporosis and its clinical efficacy.Methods:A total of 100 patients with primary osteoporosis(all were treated by our hospital from February 2017 to June 2018)were divided into two groups.The control group(50 cases)was given to menatetrenone capsules.Treatment,observation group(50 cases)combined with Yishen Gubenqiaotongtong on the basis of the treatment of the control group,6 months for a course of treatment.The bone metabolic markers,bone mineral density changes and clinical efficacy were measured before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group.After treatment,the observation group showed serum calcium(Ca),serum alkaline phosphatase(ALP)and typeⅠcollagen.The level of cross-linked C-terminal peptide(CTX-1)was lower than that of the control group.After treatment,the osteocalcin(OC)in the observation group was higher than that in the control group,and the bone mineral density(BMD)of lumbar vertebrae L2-4,femoral neck and femur trochanter in the observation group were higher than those in the control group.Conclusion:Menatetrenone soft capsule combined with Yishen Gubenyutong Decoction has good clinical effect on osteoporosis patients and it is worth further promotion in clinic.
基金the Capital Health Development Scientific Research Project(2020-2-4026)Clinical and Translational Medicine Research Fund Projects of Cancer Hospital of Chinese Academy of Medical Science(2019XK320072)
文摘Cancer-related fatigue(CRF)is associated with cancer-related anemia(CRA).As the common comorbidities of cancer,both of them can seriously affect the quality of patient life.Yishen Qutong Granules(益肾祛痛颗粒,YSQTG)have achieved good curative effects in the treatment of CRA.However,the mechanism of whether it can alleviate CRF needs further confirmation.We used network pharmacology and molecular docking to investigate the molecular mechanism and the effective compounds of the prescription.Through the analysis and research in this paper,we obtained 76 effective compounds and 76 drug-disease intersection targets to construct a network,indicating that quercetin,luteolin,baicalein,β-sitosterol and stigmasterol were possibly the most important compounds in YSQTG.The key targets of YSQTG for CRF were mainly enriched in IL-17 and TNF pathways.816 GO entries and 113 pathways were obtained by GO and KEGG enrichment,respectively,which proved that YSQTG might have a comprehensive therapeutic effect on CRF mainly through regulating IL-17,TNF,MAPK,NF-κB and chemokines,as well as cholinergic synapse and 5-HT synapse pathways.The results of molecular docking showed thatβ-sitosterol and stigmasterol could form PI-Alkyl or Alkyl hydrophobic interactions with CXCL8 and ESR1 at residues LEU25,ARG26,PHE65,ALA69 and LEU346,ALA350,LEU391,PHE404,LEU525,VAL533,respectively.In conclusion,the therapeutic effect of YSQTG on CRF is based on the comprehensive pharmacological effect of multicomponent,multitarget,and multichannel pathways.This study provides a theoretical basis for further experimental research.
文摘Objective:To discuss the clinical study on Fengshi Qutong capsules combined with diclofenac sodium in the treatment of ankylosing spondylitis.Methods:80 patients who were treated for ankylosing spondylitis from June 2019 to June 2020 were selected and divided into two groups.The experimental group was treated with Fengshi Qutong capsules combined with diclofenac sodium,and the control group was treated with sulfasalazine enteric-coated tablets.Results:The treatment efficacy,VAS score,BASDAI score,BASFI score,CRP level,TNF-α level,IL-Iβ level,and the incidence of adverse reactions between the two groups were significantly different(P<0.05).Conclusion:The application of Fengshi Qutong capsules combined with diclofenac sodium in the treatment of patients with ankylosing spondylitis is beneficial to improve the treatment efficacy,reduce the levels of CRP,TNF-α,and IL-Iβ,reduce the incidence of adverse reactions,and reduce the VAS,BASDAI and BASFI scores,rendering it of important clinical value.
基金Supported by the National Natural Science Foundation of China (No. 81873283)。
文摘Objective: To explore the potential mechanism of Yishen Qutong Granules(YSQTG) for the treatment of esophageal cancer using network pharmacology and experimental research. Methods: The effective components and molecular mechanism of YSQTG in treating esophageal cancer were expounded based on network pharmacology and molecular docking. The key compound was identified by high-performance liquid chromatography and mass spectrometry(HPLC-MS) to verify the malignant phenotype of the key compounds in the treatment of esophageal cancer. Then, the interaction proteins of key compounds were screened by pull-down assay combined with mass spectrometry. RNA-seq was used to screen the differential genes in the treatment of esophageal cancer by key compounds, and the potential mechanism of key compounds on the main therapeutic targets was verified. Results: Totally 76 effective compounds of YSQTG were found, as well as 309 related targets, and 102 drug and disease interaction targets. The drug-compound-target network of YSQTG was constructed, suggesting that quercetin, luteolin, wogonin, kaempferol and baicalein may be the most important compounds, while quercetin had higher degree value and degree centrality, which might be the key compound in YSQTG. The HPLC-MS results also showed the stable presence of quercetin in YSQTG. By establishing a protein interaction network, the main therapeutic targets of YSQTG in treating esophageal cancer were Jun proto-oncogene, interleukin-6, tumor necrosis factor, and RELA proto-oncogene. The results of cell function experiments in vitro showed that quercetin could inhibit proliferation, invasion, and clonal formation of esophageal carcinoma cells. Quercetin mainly affected the biological processes of esophageal cancer cells, such as proliferation, cell cycle, and cell metastasis. A total of 357 quercetin interacting proteins were screened, and 531 genes were significantly changed. Further pathway enrichment analysis showed that quercetin mainly affects the metabolic pathway, MAPK signaling pathway, and nuclear factor kappa B(NF-κB) signaling pathway, etc. Quercetin, the key compound of YSQTG, had stronger binding activity by molecular docking. Pull-down assay confirmed that NF-κB was a quercetin-specific interaction protein, and quercetin could significantly reduce the protein level of NF-κB, the main therapeutic target. Conclusion: YSQTG can be multi-component, multi-target, multi-channel treatment of esophageal cancer, it is a potential drug for the treatment of esophageal cancer.
文摘目的:探讨通络祛痛膏联合塞来昔布治疗风湿瘀阻证膝骨关节炎(knee osteoarthritis,KOA)的效果。方法:选取2021年1—12月徐州市中心医院骨科收治的130例风湿瘀阻证KOA患者。根据简单信封随机法将其分为对照组和观察组,各65例。对照组给予塞来昔布胶囊,观察组在对照组基础上给予通络祛痛膏。比较两组治疗前后症状评分、临床疗效及不良反应。结果:治疗后,两组KOA严重性指数(index of severity of osteoarthritis,ISOA)评分低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组临床疗效优于对照组,总有效率高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率略低于对照组,但差异无统计学意义(P>0.05),观察组未出现与中药外敷相关的局部皮肤过敏反应。结论:通络祛痛膏联合塞来昔布治疗KOA,能够缓解症状,且不增加药物相关的不良反应,用药安全性良好。
文摘目的验证益肾祛痛颗粒(Yishen Qutong Granule,YSQTKL)对小鼠乳腺癌骨转移的抑制效果并探讨其作用机制。方法随机将5周龄BABL/c小鼠分为空白组、假手术组、模型组、YSQTKL高中低剂量组,每组8只,胫骨种植4T1.2细胞制备乳腺癌骨转移模型后,分别给予蒸馏水或相应浓度YSQTKL溶液灌胃,4周后处死取材,用Micro-CT分析松质骨骨含量/组织含量[bone volume/tissue volume(BV/TV)]、松质骨厚度[trabecular bone thickness(Tb.Th)]、松质骨数目[trabecular bone number(Tb.N)]以及松质骨间隙[trabecular bone separation(Tb.Sp)]等骨质破坏情况,测量骨转移瘤瘤重,HE染色进行组织学诊断,免疫组化法检测骨桥蛋白(Osteopontin,OPN)的表达情况。结果除空白组及假手术组外,造模各组均成瘤,组织学诊断显示乳腺癌骨转移。相对于模型组,YSQTKL低剂量组瘤重更小,差异具有统计学意义(P<0.05);Micro-CT结果显示,相对于空白组及假手术组,模型组松质骨除Tb.N无差异外,BV/TV、Tb.Th以及Tb.Sp均升高(P<0.05),而YSQTKL组松质BV/TV、Tb.Th以及Tb.Sp较模型组降低(P<0.05),骨破坏程度更低;免疫组化结果显示,相对于空白组及假手术组,模型组OPN表达升高,而YSQTKL各组OPN表达较模型组低,其中低剂量组差异具有统计学意义(P<0.05)。结论益肾祛痛颗粒可抑制小鼠乳腺癌骨转移,且下调骨桥蛋白表达是其可能作用机制。